Thoughts on the Russian-Ukraine Crisis04/03/22
Whilst no two situations are the same, a key message for investors is geopolitical events tend to result in sharp sell offs, but also rebound quite quickly if economic growth is largely unaffected. This suggests being too reactionary and making sudden portfolio moves may, in hindsight, not necessarily be the right thing to do. Read more
SGH turns 20!22/07/21
This month marks a significant milestone for SGH, recently reaching our 20 year anniversary. We have had many challenges and successes along the way but most importantly our fundamental investment philosophy has remained the same. On behalf of the team at SG Hiscock & Company, I would like to thank you for supporting our business over the last 20 years. One of the great pleasures has been meeting and working with like-minded clients, clients that respect and trust what we do. We look forward to working with you for many more years to come. Steve Hiscock, Managing Director
SGH Medical Technology Fund will invest in medical technology companies, focusing on generating alpha from a portfolio of established medical technology companies, and small and unlisted companies that are driving innovation in the space. Read more
Positioning portfolios for rising inflation risk18/06/21
Since the start of the year, markets have continued to shift from hope to growth, buoyed by economies reopening and the vaccine roll-out… read more in the Money Management article with Hamish Tadgell, Portfolio Manager, SGH20.